# DESCRIPTION

## FIELD OF THE INVENTION

- relate to antibiotic derivatives

## BACKGROUND OF THE INVENTION

- introduce ribosomal interfering antibiotics
- describe ribosome structure and function
- motivate need for new treatments
- summarize crystallographic studies
- describe antibiotic binding sites
- introduce synergistic antibiotic combinations
- describe streptogramin antibiotics
- introduce Synercid
- describe Lankacidin C and lankamycin
- summarize LC and LM structures
- describe LC and LM activities
- introduce co-regulation of LC and LM production
- describe deoxylankamycin molecules
- summarize WO 03/026562
- summarize US 2009/0042186
- summarize U.S. Pat. No. 7,606,670 and U.S. Pat. No. 7,169,756

## SUMMARY OF THE INVENTION

- introduce improved antibiotic derivatives
- synergistic combinations of antibiotics
- pharmaceutical compositions of antibiotics
- synergistic combination of two antibiotic molecules
- binding to peptidyl transferase center (PTC) site
- binding to nascent peptide exit tunnel (NPET) site
- synergistic anti-bacterial effect
- Lankacidin C (LC) and Lankamycin (LM) derivatives
- Virginiamycin M, Virginiamycin S, Pleuromutilin, Chloramphenicol, Methylmycin and Clindamycin
- deoxy LM derivative
- desoamine derivative
- C-15 LM derivative
- 3-O-arcanosyl LM derivative
- Lankamycin (LM) or a derivative thereof and a type A Streptogramin (SA)
- Lankacidin C (LC) or a derivative thereof and a type B Streptogramin (SB)
- one type A Streptogramin (SA), and one type B Streptogramin (SB)
- pharmaceutical composition comprising two isolated antibiotic molecules
- PTC binding component
- NPET bonding component
- Lankacidin C (LC), and a macrolide antibiotic
- Lankacidin C (LC), and a ketolide antibiotic
- Lankacidin C (LC), and a type B Streptogramin (SB) antibiotic
- Lankamycin M (LM) or a derivative thereof, and a type A Streptogramin (SA) antibiotic
- deoxy-LM derivative, desoamine-LM derivative, C-15 LM derivative and 3-O-arcanosyl LM
- chimeric molecule comprising two portions of two different antibiotic molecules
- covalently conjugated molecule comprising at least two antibiotic molecules
- derivatives of antibiotics designed in accordance with binding sites
- improved property compared to the parent antibiotic molecule
- enhanced biological activity, reduced toxicity, enhanced permeability, enhanced bioavailability, and reduced bacterial resistance
- macrolide derivative comprising a positively charged moiety
- modification of the parent molecule to further strengthen its binding to the ribosome
- use of synergistic combinations, chimeric and conjugated molecules and improved antibiotic derivatives
- methods for producing such combinations, chimeric, conjugated and improved molecules
- prevention and treatment of bacterial infection

## DETAILED DESCRIPTION OF THE INVENTION

- introduce antibiotics LC and LM
- describe binding sites of LC and LM
- motivate synergistic anti-bacterial effect
- summarize structural results
- describe optimization of drug pair
- introduce X-ray diffraction data
- describe crystallographic and biochemical data
- establish PTC as site of LC action
- describe inhibitory effect of LC
- compare LC and SA binding sites
- describe LM binding mode and position
- compare LM and ERY binding properties
- describe synergistic action of LC and LM
- discuss evolutionary optimization of LM
- summarize significance of LC/LM synergism

### Lankacidin Binding Site

- describe LC binding pocket
- summarize interactions of LC with nucleotides
- describe hydrogen bond distance of LC
- describe re-positioning of rRNA residues
- summarize network of interactions
- describe influence of second-shell nucleotides
- describe van der Waals interactions of LC
- describe importance of macrocyclic ring conformation
- compare LC and chloramphenicol binding sites
- summarize structural basis for competition

### Lankamycin Binding Site

- describe LM binding site
- summarize hydrogen bond contacts of LM
- describe hydrophobic interactions of LM
- describe change in position of A2062
- compare LM and ERY binding
- describe rearrangement of C2610
- summarize reasons for weaker binding of LM
- describe IC50 of LM
- summarize structure of LM-D50S complex

### Lankacidin and Lankamycin Can Simultaneously Bind to the Ribosome

- introduce lankacidin and lankamycin
- compare structure of lankamycin to erythromycin
- describe competition experiments between lankacidin and erythromycin
- verify lankamycin binding to ribosome and inhibition of protein synthesis
- analyze binding of lankacidin and lankamycin using RNA probing
- describe protection of PTC nucleotide residues from CMCT modification
- describe protection of 23S rRNA residues from CMCT and DMS modification
- demonstrate simultaneous binding of lankacidin and lankamycin to ribosome
- describe effects of lankacidin and lankamycin on A2058 and A2059 residues
- discuss implications of simultaneous binding for ribosome inhibition

### LC and LM Act Synergistically Upon Bacterial Cells

- hypothesize synergy between lankacidin and lankamycin
- describe in vivo and in vitro experiments to test synergy
- analyze minimal inhibitory concentration of lankacidin and lankamycin
- discuss crystallographic structure of 50S ribosomal subunit with lankacidin and lankamycin
- compare mechanism of ribosomal inhibition to streptogramins

## Materials and Methods

- describe crystallography methods
- describe antibiotic binding and inhibition methods

### Crystallography

- describe crystal growth and soaking
- describe X-ray data collection and processing
- describe structure refinement and model building
- describe antibiotic binding site identification
- describe image generation

### Antibiotic Binding

- describe antibiotic binding assay

### Inhibition of Cell-Free Protein Synthesis by LC and LM

- describe cell-free transcription-translation assay

### Inhibition of the Peptidyl Transferase Reaction by LC

- describe puromycin assay
- describe data analysis

### RNA Probing

- describe RNA probing assay

### Cell-Free Translation System Used for Detecting Synergism In Vitro

- describe cell-free extract preparation
- describe transcription-translation reaction
- describe fluorescence data collection and analysis

## Pharmacology

- define pharmaceutical composition
- describe physiologically acceptable carriers
- describe excipients
- describe routes of administration
- describe pharmaceutical composition manufacturing
- describe oral administration formulations
- describe transmucosal administration formulations
- describe injection formulations
- describe parenteral administration formulations
- describe rectal compositions
- describe therapeutically effective amount
- describe dosage determination
- describe toxicity and therapeutic efficacy determination
- describe dosage adjustment
- describe administration intervals
- describe minimally effective concentration
- describe detection assays
- describe course of treatment
- describe pack or dispenser device
- describe labeling and instructions
- describe notice of governmental agency approval
- describe composition preparation and labeling
- describe derivatives and conjugates

### Chemical Derivatives and Conjugates

- define derivatives
- describe X-ray crystallographic analysis
- describe design and testing of desoamine derivatives

### Synthetic and Semi-Synthetic Methods for Producing Antibiotics

- describe fermentation processes
- describe synthetic and semi-synthetic methods

